Ukraine’s Pleso Therapy Raises $2.5M, Targets $20M in Revenue By Year-end
Ukrainian mental health startup Pleso Therapy is raising a new $2.5 million investment round, according to early backer and former Kyivstar CEO Petro Chernyshov.
Chernyshov says the company plans to reach $20 million in revenue by the end of 2026 and is already looking ahead to a significantly larger round in 2027, targeting a valuation of $70–80 million.
What we know
- Pleso Therapy is raising the new funds via a Convertible Loan Agreement, at a pre-money valuation of $30 million.
- Ukrainian investment syndicate ICLUB intends to participate with a total check of $500,000 at a 14% discount to the current valuation.
«This is a repeat investment for us: we first entered Pleso at an early stage with a $7 million valuation, and now we continue to support the company in a new round,» Yuriy Romanyukha, managing partner of ICLUB, told Scroll.media.
The deal has not yet closed and remains in the active fundraising stage through the ICLUB app.
- Chernyshov himself plans to participate in the round.
«I was one of the first investors in Pleso. And I’ll let you in on a secret: the company is now valued 10 times higher than when I first joined. And this time, I’m investing again,» he said.
- In May 2025, Pleso Therapy raised $1.2 million, with TA Ventures and Vchasno Group as lead investors.
- Early backers also included Oleg Oksyuk (AllRight), Valeriy Reshetnyak (Robota.ua), Vadym Synzheretskyi (BUKI), and United Angel Network.
Track record and growth plans
- Pleso Therapy was founded by Oleksandr Bondariev, Anna Lissova, Oleksii Yakubenko, and Vitalii Marchenko. While Ukraine was its launch market, the company now generates more than 60% of its revenue from Poland, and 85% overall from the EU and the UK, according to Chernyshov.
Looking 24–36 months ahead, investors see significant scaling potential across Europe.
«The ‘aha moment’ for us as investors was the acute shortage of qualified therapists in Europe and the months-long waiting lists for psychotherapy. In the UK, the average waiting time for NHS therapy exceeds 18 weeks, and in many EU countries, the situation is no better. This systemic shortage and the long queues became the decisive factor for us. Pleso closes this gap by providing access to verified therapists without waiting, using algorithmic matching and a transparent pricing model,» Romanyukha said.
- According to Chernyshov, Pleso currently works with more than 80 corporate clients, covering 25,000 employees. The company reports that 67% of clients return for a second session, and its lifetime value (LTV) to customer acquisition cost (CAC) ratio exceeds 2. «This is a very healthy indicator,» Chernyshov said.
- The company aims to reach $20 million in revenue by the end of 2026 and raise a Series A round in 2027.
«The goal is a Series A in 2027 with a valuation of $70–80 million. That implies potential growth of 2.7–3.1 times from the current valuation. This is a clear, transparent business that addresses a real problem rather than inventing one, generates foreign currency revenue, and demonstrates very strong growth,» the investor said.
Romanyukha pointed to Pleso as a showcase case for ICLUB’s angel investment model.
«Pleso Therapy is a striking example of how venture capital works in practice. Oleksandr Usyk, an active business angel at ICLUB, invested in Pleso through our community in 2025. In less than 12 months, that investment has grown approximately 4x based on the company’s new valuation. Four times in less than a year. This is exactly the type of result we aim to deliver to ICLUB investors,» he said.
Ukraine’s Pleso Therapy Raises $2.5M, Targets $20M in Revenue By Year-end
Ukrainian mental health startup Pleso Therapy is raising a new $2.5 million investment round, according to early backer and former Kyivstar CEO Petro Chernyshov.
Chernyshov says the company plans to reach $20 million in revenue by the end of 2026 and is already looking ahead to a significantly larger round in 2027, targeting a valuation of $70–80 million.
What we know
- Pleso Therapy is raising the new funds via a Convertible Loan Agreement, at a pre-money valuation of $30 million.
- Ukrainian investment syndicate ICLUB intends to participate with a total check of $500,000 at a 14% discount to the current valuation.
«This is a repeat investment for us: we first entered Pleso at an early stage with a $7 million valuation, and now we continue to support the company in a new round,» Yuriy Romanyukha, managing partner of ICLUB, told Scroll.media.
The deal has not yet closed and remains in the active fundraising stage through the ICLUB app.
- Chernyshov himself plans to participate in the round.
«I was one of the first investors in Pleso. And I’ll let you in on a secret: the company is now valued 10 times higher than when I first joined. And this time, I’m investing again,» he said.
- In May 2025, Pleso Therapy raised $1.2 million, with TA Ventures and Vchasno Group as lead investors.
- Early backers also included Oleg Oksyuk (AllRight), Valeriy Reshetnyak (Robota.ua), Vadym Synzheretskyi (BUKI), and United Angel Network.
Track record and growth plans
- Pleso Therapy was founded by Oleksandr Bondariev, Anna Lissova, Oleksii Yakubenko, and Vitalii Marchenko. While Ukraine was its launch market, the company now generates more than 60% of its revenue from Poland, and 85% overall from the EU and the UK, according to Chernyshov.
Looking 24–36 months ahead, investors see significant scaling potential across Europe.
«The ‘aha moment’ for us as investors was the acute shortage of qualified therapists in Europe and the months-long waiting lists for psychotherapy. In the UK, the average waiting time for NHS therapy exceeds 18 weeks, and in many EU countries, the situation is no better. This systemic shortage and the long queues became the decisive factor for us. Pleso closes this gap by providing access to verified therapists without waiting, using algorithmic matching and a transparent pricing model,» Romanyukha said.
- According to Chernyshov, Pleso currently works with more than 80 corporate clients, covering 25,000 employees. The company reports that 67% of clients return for a second session, and its lifetime value (LTV) to customer acquisition cost (CAC) ratio exceeds 2. «This is a very healthy indicator,» Chernyshov said.
- The company aims to reach $20 million in revenue by the end of 2026 and raise a Series A round in 2027.
«The goal is a Series A in 2027 with a valuation of $70–80 million. That implies potential growth of 2.7–3.1 times from the current valuation. This is a clear, transparent business that addresses a real problem rather than inventing one, generates foreign currency revenue, and demonstrates very strong growth,» the investor said.
Romanyukha pointed to Pleso as a showcase case for ICLUB’s angel investment model.
«Pleso Therapy is a striking example of how venture capital works in practice. Oleksandr Usyk, an active business angel at ICLUB, invested in Pleso through our community in 2025. In less than 12 months, that investment has grown approximately 4x based on the company’s new valuation. Four times in less than a year. This is exactly the type of result we aim to deliver to ICLUB investors,» he said.
